Prognostic Impact of an Oral Triglyceride Tolerance Test in Patients After Acute Ischemic Stroke

Study Overview
=================
Brief Summary
-----------------
Non-fasting triglyceride levels are thought to play a role in stroke. The investigators hypothesise that the results of a standardised oral triglyceride tolerance test in the subacute setting (3-7 days) after the first ischaemic stroke are associated with the risk of recurrent stroke within 12 months after the index event.

Detailed Description
-----------------
Since high postprandial triglycerides levels may be a risk factor for stroke, we use a combined oral triglyceride and glucose tolerance test in patients who had a first ischemic stroke. Follow-up after one year primarily assesses wether or not a recurrent stroke has occured. The glucose tolerance test is meant to identify patients with metabolic syndrome (and diabetes), since this condition is per se associated with increased levels of triglycerides. Potentially, the post-challenge triglyceride levels only play a role in patients without diabetes or metabolic syndrome. For further details see Ebinger et al. 'The Berlin 'Cream&Sugar' Study: the prognostic impact of an oral triglyceride tolerance test in patients after acute ischaemic stroke', IJS; 2010,5, 47-51.

Official Title
-----------------
The Berlin 'Cream&Sugar' Study: the Prognostic Impact of an Oral Triglyceride Tolerance Test in Patients After Acute Ischemic Stroke

Conditions
-----------------
First Ischemic Stroke

Intervention / Treatment
-----------------
* Other: oral triglyceride tolerance test (not a therapeutic intervention as such but a new diagnostic test)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 18 years First ischemic stroke Incidence within less than 7 days Informed consent obtained Exclusion Criteria: Aphasia (if hampering informed consent) Swallowing disorder Pregnancy Renal or hepatic failure Pancreatitis Cholecystolithiasis Malabsorption Lactose intolerance Psychosis Drug and/or alcohol addiction Expected life expectancyr12 months Inability to sign informed consent Acute coronary syndrome Severe heart valve disorder Heart failure (NYHA III-IV) Severe infectious/rheumatic disease Sever metabolic disease No oral glucose tolerance test in case of known diabetes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with first ischemic stroke<br> | Other: oral triglyceride tolerance test (not a therapeutic intervention as such but a new diagnostic test)<br>* see Ebinger et al., IJS, 2010<br>* Other names: cream;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrent Stroke | The primary end-point of the study is a recurrent fatal or nonfatal stroke within the first 12 months after the event. | outcome measure is assessed one year after first ischemic stroke. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MI | Myocardial infarction | one year after first ischemic stroke | 
| death | cardiovascular death (death due to any cardiovascular or cerebrovascular event) | one year after first ischemic stroke | 
| TIA | transient ischemic attack | one year after first ischemic stroke |